CDK2 and hepatocellular carcinoma: Activation of ERK enhanced the expression of c-Myc that downregulated p21 and enhanced the cell cycle members cyclin-dependent kinase-2 (CDK-2) and cyclin D1 in hepatocellular carcinoma [59].